Stocktoria
CYTOKINETICS INC CYTK
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-04-29
CYTOKINETICS INC statistics & valuation
Market cap$10.2B
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Net margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% |
| FCF margin | -607.5% | -2164.1% | -5521.2% | -328.6% | -271.8% |
| Return on assets | -55.1% | -42.1% | -63.8% | -38.3% | -25.6% |
| Return on equity | 119.0% | 435.5% | 136.2% | 360.5% | -88.3% |
| Debt / equity | -0.37× | -4.58× | -1.65× | -6.02× | 0.19× |
| Current ratio | 4.53 | 6.17 | 6.12 | 9.40 | 7.45 |
| Revenue growth | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% |
Source: SEC EDGAR filings · CIK 0001061983 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.